Phenylethylamine for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Phenylethylamine for Health & Longevity

Created on 09/26/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Phenylethylamine is a natural brain chemical, sold as an inexpensive oral supplement, used for a brief lift in focus, mood and motivation. Human evidence for benefit is thin: only small reports lacking a comparison group, from one research group, paired with a prescription drug. Other claims rest on animal work, theory and personal accounts. As a short-acting, experimental stimulant, its safety depends heavily on heart health, medications and product quality. (Full Review)

Protocol

Common supplement protocol
100–500 mg PEA hydrochloride orally
Per session, on demanding days rather than daily; usually a single dose per session
Time of day
Morning or before demanding tasks
Avoided in the evening because of stimulant effects on sleep
Baseline biomarkers
Normal resting blood pressure and heart rate
Prerequisites for use; low urinary phenylacetic acid was proposed as a marker for selecting depressed candidates
Time to effect
Mood improvement in depression
Rapid
As rapidly as with amphetamine in the depression series (with selegiline); responders stayed improved for 20–50 weeks
Acute effects
Within minutes
Fade within about an hour

Benefits

Contraindications
  • Monoamine oxidase inhibitors (MAOIs) (phenelzine, tranylcypromine, isocarboxazid, linezolid, methylene blue), including 14 days after the last dose
  • Uncontrolled hypertension (≥140/90 mmHg despite treatment) or blood pressure crisis history
  • Recent heart attack or stroke (<6 months), known arrhythmia, or structural heart disease
  • Pheochromocytoma (an adrenaline-secreting tumor) or untreated hyperthyroidism (overactive thyroid)
  • Bipolar disorder, schizophrenia or other psychotic disorders, and panic disorder
  • History of stimulant use disorder
  • Pregnancy and breastfeeding
  • Athletes subject to WADA in-competition testing
    •
Key Interactions
  • Selective MAO-B inhibitors (selegiline, rasagiline, safinamide): caution, physician-supervised only
  • Prescription stimulants (amphetamine, lisdexamfetamine, methylphenidate): caution
  • Desipramine: avoid combining
  • Other antidepressants (sertraline, venlafaxine, bupropion): caution
  • Serotonergic opioid pain relievers (meperidine, pentazocine, tramadol): avoid combining
  • Antihypertensives (blood-pressure-lowering drugs such as amlodipine, lisinopril, losartan): monitor
  • Decongestants (pseudoephedrine, phenylephrine): caution
  • Dextromethorphan cough products: avoid combining
  • MAO-B–competing amines (hordenine, N-methyltyramine): caution
  • Stimulant botanicals and caffeine (bitter orange/synephrine, yohimbine, caffeine, guarana): caution
  • Mood-active supplements (St. John's wort, L-phenylalanine, L-tyrosine): monitor
  • High-intensity or heat exposure: monitor
  • Surgery and anesthesia: caution (PEA stopped at least 2 weeks before)
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Blood pressure surges and stroke; anxiety, mania and psychosis; headache and migraine trigger; adulterated or mislabeled products; impaired insulin sensitivity
    •
  • Speculative: Insomnia and sleep disruption; dependence and misuse; dopaminergic neurotoxicity
    •

Monitoring

Marker Target Why
Home blood pressure <120/80 mmHg Detects blood-pressure rise
Resting heart rate 50–70 beats/min Detects stimulant-driven fast heart rate
Resting ECG Normal sinus rhythm; QTc <450 ms (men), <460 ms (women) Screens for arrhythmia before stimulant use
Fasting glucose 75–90 mg/dL Tracks glucose control
Fasting insulin 2–6 µIU/mL Early sign of insulin resistance
HbA1c <5.4% Longer-term glucose trend
TSH 1.0–2.5 mIU/L Excludes overactive thyroid
PHQ-9 score <5 Tracks mood response
Urinary phenylacetic acid No established target; track change from own baseline Research marker of PEA activity

Cadence: Baseline before starting; blood pressure and pulse 30–60 minutes after each of the first 3 doses and after any dose increase; mood questionnaire at 4 weeks; fasting glucose, insulin and HbA1c at 3 months, then every 6–12 months with regular use

Qualitative Assessment

  • Focus and task persistence during work sessions
  • Mood and motivation across the day
  • Sleep onset time and sleep quality
  • Anxiety, irritability or jitteriness
  • Palpitations, headache or flushing after dosing
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.